Pharmacological and dietary-supplement treatments for autism spectrum disorder: a systematic review and network meta-analysis.
ADHD
Anxiety
Autism
Caregiver stress
Irritability
Meta-analysis
Response
Restricted and repetitive behaviors
Social communication
Treatment
Journal
Molecular autism
ISSN: 2040-2392
Titre abrégé: Mol Autism
Pays: England
ID NLM: 101534222
Informations de publication
Date de publication:
04 03 2022
04 03 2022
Historique:
received:
15
04
2021
accepted:
02
02
2022
entrez:
5
3
2022
pubmed:
6
3
2022
medline:
28
4
2022
Statut:
epublish
Résumé
There is still no approved medication for the core symptoms of autism spectrum disorder (ASD). This network meta-analysis investigated pharmacological and dietary-supplement treatments for ASD. We searched for randomized-controlled-trials (RCTs) with a minimum duration of seven days in ClinicalTrials.gov, EMBASE, MEDLINE, PsycINFO, WHO-ICTRP (from inception up to July 8, 2018), CENTRAL and PubMed (up to November 3, 2021). The co-primary outcomes were core symptoms (social-communication difficulties-SCD, repetitive behaviors-RB, overall core symptoms-OCS) measured by validated scales and standardized-mean-differences (SMDs). Associated symptoms, e.g., irritability/aggression and attention-deficit/hyperactivity disorder (ADHD) symptoms, dropouts and important side-effects, were investigated as secondary outcomes. Studies in children/adolescents and adults were analyzed separately in random-effects pairwise and network meta-analyses. We analyzed data for 41 drugs and 17 dietary-supplements, from 125 RCTs (n = 7450 participants) in children/adolescents and 18 RCTs (n = 1104) in adults. The following medications could improve at least one core symptom domain in comparison with placebo: aripiprazole (k = 6 studies in analysis, SCD: SMD = 0.27 95% CI [0.09, 0.44], RB: 0.48 [0.26, 0.70]), atomoxetine (k = 3, RB:0.49 [0.18, 0.80]), bumetanide (k = 4, RB: 0.35 [0.09, 0.62], OCS: 0.61 [0.31, 0.91]), and risperidone (k = 4, SCM: 0.31 [0.06, 0.55], RB: 0.60 [0.29, 0.90]; k = 3, OCS: 1.18 [0.75, 1.61]) in children/adolescents; fluoxetine (k = 1, RB: 1.20 [0.45, 1.96]), fluvoxamine (k = 1, RB: 1.04 [0.27, 1.81]), oxytocin (k = 6, RB:0.41 [0.16, 0.66]) and risperidone (k = 1, RB: 0.97 [0.21,1.74]) in adults. There were some indications of improvement by carnosine, haloperidol, folinic acid, guanfacine, omega-3-fatty-acids, probiotics, sulforaphane, tideglusib and valproate, yet imprecise and not robust. Confidence in these estimates was very low or low, except moderate for oxytocin. Medications differed substantially in improving associated symptoms, and in their side-effect profiles. Most of the studies were inadequately powered (sample sizes of 20-80 participants), with short duration (8-13 weeks), and about a third focused on associated symptoms. Networks were mainly star-shaped, and there were indications of reporting bias. There was no optimal rating scale measuring change in core symptoms. Some medications could improve core symptoms, although this could be likely secondary to the improvement of associated symptoms. Evidence on their efficacy and safety is preliminary; therefore, routine prescription of medications for the core symptoms cannot be recommended. Trial registration PROSPERO-ID CRD42019125317.
Sections du résumé
BACKGROUND
There is still no approved medication for the core symptoms of autism spectrum disorder (ASD). This network meta-analysis investigated pharmacological and dietary-supplement treatments for ASD.
METHODS
We searched for randomized-controlled-trials (RCTs) with a minimum duration of seven days in ClinicalTrials.gov, EMBASE, MEDLINE, PsycINFO, WHO-ICTRP (from inception up to July 8, 2018), CENTRAL and PubMed (up to November 3, 2021). The co-primary outcomes were core symptoms (social-communication difficulties-SCD, repetitive behaviors-RB, overall core symptoms-OCS) measured by validated scales and standardized-mean-differences (SMDs). Associated symptoms, e.g., irritability/aggression and attention-deficit/hyperactivity disorder (ADHD) symptoms, dropouts and important side-effects, were investigated as secondary outcomes. Studies in children/adolescents and adults were analyzed separately in random-effects pairwise and network meta-analyses.
RESULTS
We analyzed data for 41 drugs and 17 dietary-supplements, from 125 RCTs (n = 7450 participants) in children/adolescents and 18 RCTs (n = 1104) in adults. The following medications could improve at least one core symptom domain in comparison with placebo: aripiprazole (k = 6 studies in analysis, SCD: SMD = 0.27 95% CI [0.09, 0.44], RB: 0.48 [0.26, 0.70]), atomoxetine (k = 3, RB:0.49 [0.18, 0.80]), bumetanide (k = 4, RB: 0.35 [0.09, 0.62], OCS: 0.61 [0.31, 0.91]), and risperidone (k = 4, SCM: 0.31 [0.06, 0.55], RB: 0.60 [0.29, 0.90]; k = 3, OCS: 1.18 [0.75, 1.61]) in children/adolescents; fluoxetine (k = 1, RB: 1.20 [0.45, 1.96]), fluvoxamine (k = 1, RB: 1.04 [0.27, 1.81]), oxytocin (k = 6, RB:0.41 [0.16, 0.66]) and risperidone (k = 1, RB: 0.97 [0.21,1.74]) in adults. There were some indications of improvement by carnosine, haloperidol, folinic acid, guanfacine, omega-3-fatty-acids, probiotics, sulforaphane, tideglusib and valproate, yet imprecise and not robust. Confidence in these estimates was very low or low, except moderate for oxytocin. Medications differed substantially in improving associated symptoms, and in their side-effect profiles.
LIMITATIONS
Most of the studies were inadequately powered (sample sizes of 20-80 participants), with short duration (8-13 weeks), and about a third focused on associated symptoms. Networks were mainly star-shaped, and there were indications of reporting bias. There was no optimal rating scale measuring change in core symptoms.
CONCLUSIONS
Some medications could improve core symptoms, although this could be likely secondary to the improvement of associated symptoms. Evidence on their efficacy and safety is preliminary; therefore, routine prescription of medications for the core symptoms cannot be recommended. Trial registration PROSPERO-ID CRD42019125317.
Identifiants
pubmed: 35246237
doi: 10.1186/s13229-022-00488-4
pii: 10.1186/s13229-022-00488-4
pmc: PMC8896153
doi:
Substances chimiques
Oxytocin
50-56-6
Risperidone
L6UH7ZF8HC
Types de publication
Journal Article
Meta-Analysis
Research Support, Non-U.S. Gov't
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
10Informations de copyright
© 2022. The Author(s).
Références
Neuropsychopharmacology. 2010 Mar;35(4):990-8
pubmed: 20010551
Clin Psychopharmacol Neurosci. 2020 May 31;18(2):203-213
pubmed: 32329301
Pediatrics. 2012 May;129(5):e1301-10
pubmed: 22529279
Arch Gen Psychiatry. 1996 Nov;53(11):1001-8
pubmed: 8911223
Res Synth Methods. 2015 Dec;6(4):293-309
pubmed: 26287812
J Pers Med. 2021 Aug 11;11(8):
pubmed: 34442428
Sci Transl Med. 2019 May 8;11(491):
pubmed: 31043522
Psychiatr Clin North Am. 2020 Dec;43(4):629-645
pubmed: 33126999
J Am Acad Child Adolesc Psychiatry. 2006 Sep;45(9):1114-23
pubmed: 16926619
Autism. 2021 Nov;25(8):2152-2161
pubmed: 34308675
Sci Transl Med. 2019 May 8;11(491):
pubmed: 31043521
Schizophr Res. 2013 Dec;151(1-3):209-14
pubmed: 24262679
J Clin Epidemiol. 2004 Dec;57(12):1232-6
pubmed: 15617948
Cochrane Database Syst Rev. 2013 Aug 20;(8):CD004677
pubmed: 23959778
J Autism Dev Disord. 2013 Aug;43(8):1773-83
pubmed: 23212807
BMJ Open. 2016 Jul 08;6(7):e010919
pubmed: 27401359
Eur Child Adolesc Psychiatry. 2021 Jun;30(6):961-984
pubmed: 32666205
Eur Neuropsychopharmacol. 2021 Jul;48:3-31
pubmed: 34158222
J Neurochem. 2019 Dec;151(5):642-655
pubmed: 31325179
Psychol Med. 2017 May;47(7):1323-1334
pubmed: 28091344
N Engl J Med. 2021 Oct 14;385(16):1462-1473
pubmed: 34644471
Br J Clin Pharmacol. 2021 Mar;87(3):1069-1081
pubmed: 32643213
Int J Epidemiol. 2012 Jun;41(3):818-27
pubmed: 22461129
J Clin Epidemiol. 2022 Feb;142:271-279
pubmed: 33171273
Pharmacopsychiatry. 2017 Jan;50(1):19-25
pubmed: 27299475
J Autism Dev Disord. 1980 Mar;10(1):91-103
pubmed: 6927682
Prog Neuropsychopharmacol Biol Psychiatry. 2021 Aug 30;110:110326
pubmed: 33857522
Pediatrics. 2019 Nov;144(5):
pubmed: 31586029
Mol Autism. 2018 Feb 22;9:12
pubmed: 29484149
BMJ. 2013 Feb 12;346:f707
pubmed: 23403829
Res Synth Methods. 2016 Sep;7(3):236-63
pubmed: 26754852
J Psychopharmacol. 2018 Jan;32(1):3-29
pubmed: 29237331
Am J Psychiatry. 2005 Jun;162(6):1142-8
pubmed: 15930063
Front Psychiatry. 2021 Sep 30;12:669089
pubmed: 34658941
Am J Ment Defic. 1985 Mar;89(5):492-502
pubmed: 3158201
J Child Adolesc Psychopharmacol. 2005 Aug;15(4):682-92
pubmed: 16190799
Eur Neuropsychopharmacol. 2021 Jul;48:49-88
pubmed: 33781629
Proc Natl Acad Sci U S A. 2014 Oct 28;111(43):15550-5
pubmed: 25313065
Epilepsy Behav. 2017 Nov;76:24-31
pubmed: 28931473
J Autism Dev Disord. 2017 Jun;47(6):1595-1604
pubmed: 28255761
J Autism Dev Disord. 2021 Jun 10;:
pubmed: 34110556
J Autism Dev Disord. 2021 Aug;51(8):2959-2972
pubmed: 33151500
Am J Psychiatry. 2012 Mar;169(3):292-9
pubmed: 22193531
J Autism Dev Disord. 2008 Aug;38(7):1311-9
pubmed: 18095149
Pediatrics. 2016 Feb;137 Suppl 2:S124-35
pubmed: 26908468
Int J Epidemiol. 2002 Feb;31(1):140-9
pubmed: 11914310
Cochrane Database Syst Rev. 2019 Oct 3;10:ED000142
pubmed: 31643080
BMJ. 2004 Jan 3;328(7430):22-4
pubmed: 14703540
Transl Psychiatry. 2018 Dec 4;8(1):257
pubmed: 30514927
Nat Rev Drug Discov. 2018 Apr;17(4):280-299
pubmed: 29217836
World Psychiatry. 2020 Jun;19(2):214-232
pubmed: 32394557
Med Clin (Barc). 2016 Sep 16;147(6):262-6
pubmed: 27040178
Mol Autism. 2020 Aug 26;11(1):66
pubmed: 32847616
Transl Psychiatry. 2017 May 9;7(5):e1124
pubmed: 28485727
J Clin Epidemiol. 2012 Jun;65(6):602-9
pubmed: 22424985
Cochrane Database Syst Rev. 2005 Oct 19;(4):CD003497
pubmed: 16235322
Mol Autism. 2021 Feb 3;12(1):6
pubmed: 33536055
J Clin Epidemiol. 2002 Aug;55(8):783-6
pubmed: 12384192
Cochrane Database Syst Rev. 2012 Mar 14;(3):CD008372
pubmed: 22419332
J Med Chem. 2017 Nov 22;60(22):9114-9141
pubmed: 29039668
J Child Psychol Psychiatry. 2021 Jun;62(6):680-700
pubmed: 32845025
J Clin Epidemiol. 2015 Jan;68(1):52-60
pubmed: 25304503
BMJ. 2011 Oct 18;343:d5928
pubmed: 22008217
J Child Adolesc Psychopharmacol. 2019 Apr;29(3):168-180
pubmed: 30707602
Brain Sci. 2021 Jul 09;11(7):
pubmed: 34356141
J Am Acad Child Adolesc Psychiatry. 1993 Nov;32(6):1283-91
pubmed: 8282676
PLoS Med. 2020 Apr 3;17(4):e1003082
pubmed: 32243458
Int Clin Psychopharmacol. 2006 Nov;21(6):363-7
pubmed: 17012983
Cochrane Database Syst Rev. 2016 Jun 26;(6):CD009043
pubmed: 27344135
Cochrane Database Syst Rev. 2017 Nov 21;11:CD011144
pubmed: 29159857
Transl Psychiatry. 2015 Sep 22;5:e640
pubmed: 26393486
J Am Acad Child Adolesc Psychiatry. 2021 Jan;60(1):35-45
pubmed: 32387445
Pharmacol Ther. 2022 Feb;230:107939
pubmed: 34174273
Res Synth Methods. 2019 Sep;10(3):398-419
pubmed: 30854785
Pediatrics. 2020 Apr;145(Suppl 1):S20-S29
pubmed: 32238528
J Pediatr. 2016 Mar;170:45-53.e1-4
pubmed: 26746121
Mol Autism. 2021 May 25;12(1):38
pubmed: 34034808
BMC Med Res Methodol. 2015 Jul 31;15:58
pubmed: 26227148
Acta Psychiatr Scand. 2017 Jan;135(1):8-28
pubmed: 27624381
Front Psychiatry. 2021 Aug 24;12:701729
pubmed: 34504446
Int J Neuropsychopharmacol. 2006 Apr;9(2):209-13
pubmed: 16316486
J Child Adolesc Psychopharmacol. 2016 Nov;26(9):774-783
pubmed: 26889605
PLoS One. 2013 Oct 03;8(10):e76654
pubmed: 24098547
J Autism Dev Disord. 2018 Sep;48(9):3228-3232
pubmed: 29644586